Richard S Finn Selected Research

Richard S Finn Research Topics

Disease

79	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 02/2009
57	Neoplasms (Cancer) 06/2022 - 12/2004
46	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2003
10	Hypertension (High Blood Pressure) 01/2022 - 04/2011
9	Neutropenia 01/2021 - 01/2015
8	Fatigue 01/2021 - 04/2011
8	Liver Neoplasms (Liver Cancer) 12/2020 - 01/2012
7	Disease Progression 01/2022 - 09/2009
5	Liver Diseases (Liver Disease) 11/2021 - 01/2018
5	Cholangiocarcinoma 10/2019 - 04/2011
4	Triple Negative Breast Neoplasms 08/2015 - 11/2007
4	Diarrhea 03/2015 - 12/2008
3	Inflammation (Inflammations) 01/2022 - 01/2019
3	Circulating Neoplastic Cells 01/2022 - 10/2020
3	Febrile Neutropenia 01/2021 - 11/2016
3	Infections 01/2021 - 07/2004
3	Fibrosis (Cirrhosis) 01/2021 - 01/2019
3	Leukopenia 01/2019 - 03/2015
3	Exanthema (Rash) 02/2017 - 12/2008
3	Carcinogenesis 02/2016 - 02/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2013 - 07/2010
2	Pain (Aches) 01/2021 - 01/2020
2	Back Pain (Backache) 01/2020 - 01/2015
2	Proteinuria 10/2019 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 12/2013
2	Hyponatremia 11/2014 - 10/2013
2	Stomach Neoplasms (Stomach Cancer) 04/2013 - 03/2010
2	Retinoblastoma (Glioblastoma, Retinal) 03/2011 - 01/2009
1	Hepatitis 01/2022
1	Ascites 06/2021

Drug/Important Bio-Agent (IBA)

28	Sorafenib (BAY 43-9006)FDA Link 04/2022 - 12/2010
24	ErbB Receptors (EGF Receptor)IBA 01/2022 - 12/2008
23	palbociclibIBA 01/2021 - 01/2009
15	Biomarkers (Surrogate Marker)IBA 06/2022 - 12/2013
14	Hormones (Hormone)IBA 01/2022 - 05/2013
12	Estrogen ReceptorsIBA 10/2020 - 01/2009
11	Letrozole (Femara)FDA LinkGeneric 01/2021 - 01/2015
11	Trastuzumab (Herceptin)FDA Link 02/2015 - 01/2003
10	RamucirumabIBA 01/2022 - 12/2013
10	Phosphotransferases (Kinase)IBA 02/2019 - 11/2007
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2009
9	Proteins (Proteins, Gene)FDA Link 10/2019 - 12/2008
8	Bevacizumab (Avastin)FDA Link 04/2022 - 02/2009
8	pembrolizumabIBA 04/2022 - 01/2018
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022 - 10/2014
8	Lapatinib (GW572016)FDA Link 02/2014 - 12/2008
7	lenvatinibIBA 04/2022 - 01/2018
7	Pharmaceutical PreparationsIBA 01/2022 - 12/2012
7	Monoclonal AntibodiesIBA 06/2019 - 01/2003
6	Tyrosine Kinase InhibitorsIBA 01/2022 - 12/2008
6	Cyclin-Dependent Kinase 4IBA 01/2021 - 01/2015
5	atezolizumabIBA 04/2022 - 01/2020
5	Phenobarbital (Luminal)FDA Link 11/2020 - 11/2007
5	Cyclin-Dependent Kinases (cdk Proteins)IBA 02/2019 - 01/2015
5	human ERBB2 proteinIBA 11/2016 - 12/2008
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2018
4	regorafenibIBA 01/2019 - 01/2017
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2018 - 09/2012
4	brivanibIBA 11/2014 - 04/2011
4	Paclitaxel (Taxol)FDA LinkGeneric 11/2009 - 12/2008
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 09/2012
3	NivolumabIBA 01/2022 - 01/2018
3	Messenger RNA (mRNA)IBA 01/2022 - 12/2008
3	AlbuminsIBA 09/2021 - 01/2021
3	Fetal Proteins (Fetoprotein)IBA 06/2021 - 01/2019
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2014 - 03/2010
3	Dasatinib (BMS 354825)FDA Link 05/2013 - 11/2007
3	Epidermal Growth Factor (EGF)IBA 01/2013 - 12/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2013 - 02/2009
2	BilirubinIBA 09/2021 - 04/2021
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020 - 03/2013
2	Peptides (Polypeptides)IBA 01/2020 - 09/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 09/2012
2	CreatinineIBA 10/2019 - 01/2019
2	Cyclin DIBA 02/2019 - 01/2009
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 01/2018 - 05/2013
2	infigratinibIBA 01/2018 - 05/2013
2	Gemcitabine FDA Link 01/2018 - 12/2014
2	VimentinIBA 01/2018 - 11/2007
2	Fulvestrant (Faslodex)FDA Link 02/2015 - 03/2013
2	Everolimus FDA Link 02/2015 - 12/2013
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 06/2013 - 04/2013
2	Biological ProductsIBA 06/2013 - 03/2011
2	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 08/2010
2	dacomitinibIBA 01/2013 - 09/2012
2	src-Family KinasesIBA 11/2011 - 08/2010
2	AZD 6244IBA 07/2010 - 03/2010
2	Progesterone Receptors (Progesterone Receptor)IBA 09/2009 - 08/2009
2	Capecitabine (Xeloda)FDA Link 12/2008 - 01/2008
1	roblitinibIBA 06/2022
1	spartalizumabIBA 06/2022
1	Combined Antibody TherapeuticsIBA 05/2021

Therapy/Procedure

58	Therapeutics 01/2022 - 01/2003
10	Liver Transplantation 01/2019 - 12/2010
8	Drug Therapy (Chemotherapy) 01/2021 - 10/2007
2	Immunotherapy 01/2022 - 01/2021
2	Drug Tapering 12/2020 - 12/2019
2	Transplantation 10/2020 - 10/2016
2	Radiofrequency Ablation 01/2018 - 01/2017
1	Duration of Therapy 06/2021